In an NK cell-based anti-melanoma experiment, GPA7, a TCR-like nanobody, was fused to the intracellular domain of CD3ζ to target the melanoma-associated gp100/HLA-A2 complex expressed in melanoma cells. This evidence concerns the gene PMEL and melanoma.